BASKING RIDGE, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter and nine-months ended September 30, 2019 after the close of the market on Wednesday, November 13, 2019. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.
|Wednesday, November 13th @ 4:30pm Eastern Time|
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.
For more information, visit www.electrocore.com.
LifeSci Public Relations